Abraxis BioScience, Inc. (Acquired by Celgene Corporation)

171 articles with Abraxis BioScience, Inc. (Acquired by Celgene Corporation)

• Ex-Abraxis BioScience, Inc. Cancer Researcher-Turned-Billionaire Starts New Company

  1/29/2013

• Celgene (Summit, New Jersey) Completes Acquisition of Abraxis BioScience, Inc.

  10/15/2010

• Celgene Corporation and Abraxis BioScience, Inc. Announce Shareholder Vote in Favor of Merger

  10/14/2010

• Antitope Announces EpiScreen Collaboration with Abraxis BioScience, Inc.

  9/28/2010

• Celgene Corporation/Abraxis BioScience, Inc. Receive Verbal Confirmation of Early Termination of Hart-Scott-Rodino (HSR) 30-Day Waiting Period

  8/4/2010

• Abraxis BioScience, Inc. and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand

  7/29/2010

• Abraxis BioScience, Inc.'s ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer

  7/23/2010

• Celgene to Buy Abraxis BioScience, Inc. for $2.9 Billion

  6/30/2010

• Abraxis BioScience, Inc. Release: Among the Toughest Cancers to Treat, New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma

  6/8/2010

• Abraxis BioScience, Inc. Release: American Society of Clinical Oncology Presentations Offer New Insights into Role of nab(R)-Chemotherapy Based Breast Cancer Chemotherapy Treatment

  6/8/2010

• Abraxis BioScience, Inc. Release: Results of Phase 3 ABRAXANE(R) Combination Trial In First-Line Non-Small Cell Lung Cancer Show 31 Percent Improvement In Response Rate Compared With Taxol Combination

  6/7/2010

• Abraxis BioScience, Inc. Release:New Data Demonstrates Potential of ABRAXANE in Difficult-to-Treat Refractory Invasive Bladder Cancer

  6/2/2010

• Abraxis BioScience, Inc.'s Second Trial with ABRAXANE to Demonstrate Increased Survival in Patients with Advanced Pancreatic Cancer

  5/21/2010

• Abraxis BioScience, Inc.: Over 30 Scientific Presentations at Abraxis BioScience, Inc. Exploring ABRAXANE's Expanded Potential in Multiple Difficult-to-Treat Cancers

  5/18/2010

• Abraxis BioScience, Inc. Reports First Quarter 2010 Financial Results

  5/6/2010

• Abraxis BioScience, Inc.'s ABRAXANE(R) in Combination with Bevacizumab Shows Promise in New Model of Triple Negative Breast Cancer

  4/20/2010

• Abraxis BioScience, Inc.'s ABRAXANE(R) In Combination With Gemcitabine Increases Survival In First-Line Treatment Of Advanced Pancreatic Cancer In Phase I/II Study

  4/19/2010

• Abraxis BioScience, Inc. Hires Advisers to Weigh Sale of Company

  4/14/2010

• Scottish Medicines Consortium Accepts Abraxis BioScience, Inc.'s ABRAXANE(R) for Use within National Health Service for Scotland

  4/13/2010

• Abraxis BioScience, Inc. Founder & Executive Chairman to Present at 7th Annual World Health Care Congress

  4/13/2010